Brief: Lee's Pharmaceutical Says Unit's New Drug Application Of Natulan Accepted For Review
08/05/2020 15:44
May 8 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* UNIT'S NEW DRUG APPLICATION OF NATULAN ACCEPTED FOR REVIEW
BY
NMPA
* GROUP EXPECTED TO SUBMIT PRIORITY REVIEW APPLICATION OF
NDA BY
END OF MAY 2020
Source text for Eikon: ID:nHKS40WBZD
Further company coverage: 0950.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lees Pharmaceutical Holdings
See all newsBrief: Lee's Pharmaceutical Announces Share Repurchase Program Under Repurchase Mandate
Brief: Lee's Pharmaceutical To Receive Funding From Gates Foundation For Synthetic Surfactant Project
Brief: Lee's Pharmaceutical Says Zhaoke Hefei To Contribute Rmb25 Million To Partnership Fund
Brief: Lee's Pharmaceutical Declares Final Dividend Of HK2.3 Cents Per Share
Brief: Lee's Pharmaceutical Reports Approval Of Intrarosa By NMPA